Abstract:Recently, we and others reported that aged-tau knockout mice exhibit behavioural deficits, arguing for a role of functional tau protein in brain health. We also showed that these mice exhibit iron-dependent neurodegeneration and clioquinol (CQ), a drug that binds to iron, prevented the development of symptoms in tau KO mice. However, prospective treatments for neurodegenerative disorders will need to confer benefit to symptomatic patients. Here, CQ was given to symptomatic 12-months old tau KO mice to test whether this treatment was effective. Tau knockout mice (tau KO) and background C57BL6/SV129 control mice (WT), at 12 months of age, were treated with CQ chow (30mg/kg body weight /day) for 5.5 months. We monitored the mice by pole test and rotarod every three weeks during treatment period, and terminated this study when the mice were 17-months of age. Y maze tests were performed before the mice being euthanized for biochemical studies. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by HPLC. Before treatment commenced, tau KO mice exhibited cognitive loss (y-maze) and parkinsonism (rotarod, pole test), as previously reported. Over the course of the study, CQ treatment reversed the motor and cognitive impairment as evidenced by improvement in the Pole test (P<0.001) and Rotarod test (P=0.008) and y-maze (P=0.038). Restoration of behavioral disability reflected preservation of neuroanatomical features including enlargement of cortical thickness (P=0.026) and striatal enlargement (P=0.001) and reduction of the lateral ventricular area (P<0.001) at the conclusion of the study. These benefits conferred by CQ treatment could be attributed to reduction in iron load in the brain since treatment with CQ for 5.5 months had decreased iron in the brain (P=0.003 for hippocampus, and P=0.007 for SN) but not liver. Copper and zinc levels were unaffected. Here we report that iron chelation by CQ rescued several neurodegenerative phenotypes of aged tau KO mice, further supporting our hypothesis that tau plays a crucial role in age-related diseases. Importantly, these benefits were conferred to mice that began treatment after symptom manifestation, highlighting the potential for iron chelation approaches as disease modifying therapeutics for neurodegenerative diseases.

Loss of Tau Induces Age-Dependent Anaemia with Reduced Longevity in Mice

O4‐08‐03: Loss of Tau Induces Age‐dependent Neurodegeneration

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Motor and Cognitive Deficits in Aged Tau Knockout Mice in Two Background Strains

Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau.

Tau Deficiency Induces Parkinsonism with Dementia by Impairing APP-mediated Iron Export

Tau-mediated Iron Export Prevents Ferroptotic Damage after Ischemic Stroke

Rescue of Behavioral and neurodegenerative phenotypes in symptomatic tau KO mice: Therapeutic implications for neurodegenerative diseases

Tau Deficiency Down-Regulated Transcription Factor Orthodenticle Homeobox 2 Expression in the Dopaminergic Neurons in Ventral Tegmental Area and Caused No Obvious Motor Deficits in Mice

Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.

Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent

Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice

High Dietary Iron Disrupts Iron Homeostasis And Induces Amyloid-Beta And Phospho-Tau Expression In The Hippocampus Of Adult Wild-Type And App/Ps1 Transgenic Mice

Expression of A152T Human Tau Causes Age‐dependent Neuronal Dysfunction and Loss in Transgenic Mice

Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau

Tau knockout exacerbates degeneration of parvalbumin‐positive neurons in substantia nigra pars reticulata in Parkinson's disease‐related α‐synuclein A53T mice